Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.0%

1 terminated/withdrawn out of 101 trials

Success Rate

99.0%

+12.5% vs industry average

Late-Stage Pipeline

2%

2 trials in Phase 3/4

Results Transparency

2%

2 of 100 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
82(81.2%)
Phase 1
11(10.9%)
Early Phase 1
6(5.9%)
Phase 3
1(1.0%)
Phase 4
1(1.0%)
101Total
N/A(82)
Phase 1(11)
Early Phase 1(6)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (101)

Showing 20 of 101 trials
NCT01676493Phase 3Terminated

A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain

Role: lead

NCT01322360Phase 4Completed

Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects

Role: lead

NCT01107353Not ApplicableCompleted

Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions

Role: lead

NCT01331434Not ApplicableCompleted

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Role: lead

NCT00618046Not ApplicableCompleted

Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

Role: lead

NCT00601328Not ApplicableCompleted

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Role: lead

NCT01102478Not ApplicableCompleted

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

Role: lead

NCT01659918Early Phase 1Completed

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

Role: lead

NCT01009892Phase 1Completed

Food Effect Study of Codeine Sulfate

Role: lead

NCT00602342Not ApplicableCompleted

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

Role: lead

NCT01570907Not ApplicableCompleted

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

Role: lead

NCT00602524Not ApplicableCompleted

Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions

Role: lead

NCT01331447Not ApplicableCompleted

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Role: lead

NCT00602407Not ApplicableCompleted

Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions

Role: lead

NCT00894088Not ApplicableCompleted

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions

Role: lead

NCT00601874Not ApplicableCompleted

Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions

Role: lead

NCT01132729Not ApplicableCompleted

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

Role: lead

NCT00602173Not ApplicableCompleted

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

Role: lead

NCT00893919Not ApplicableCompleted

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

Role: lead

NCT01009853Phase 1Completed

Steady State Study of Codeine Sulfate

Role: lead